Inventor
BOON THIERRY
BE13 patents
⚠️ This page may combine multiple inventors who share the name “BOON THIERRY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
LUDWIG INST CANCER RES
8 patentsUS5405940AApr 11, 1995
Isolated nonapeptides derived from MAGE genes and uses thereof
LUDWIG INST CANCER RES129 citations98
US5342774AAug 30, 1994
Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
LUDWIG INST CANCER RES232 citations98
US6034214AMar 7, 2000
Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells
LUDWIG INST CANCER RES40 citations96
US6488932B1Dec 3, 2002
Method for treating cancer by administering MAGE-derived peptides
LUDWIG INST CANCER RES25 citations92
US5925729AJul 20, 1999
Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
LUDWIG INST CANCER RES31 citations92
US7547439B1Jun 16, 2009
Tumor rejection antigens
LUDWIG INST CANCER RES5 citations71
US7041502B2May 9, 2006
Isolated peptides which bind to HLA-B18 molecules and uses thereof
LUDWIG INST CANCER RES2 citations58
US7923534B1Apr 12, 2011
Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3
LUDWIG INST CANCER RES0 citations51
LUDWIG INST FOR CANCER RES LTD
3 patentsUS9518112B2Dec 13, 2016
TGF-β1 specific antibodies and methods and uses thereof
LUDWIG INST FOR CANCER RES LTD24 citations93
US11957751B2Apr 16, 2024
TGF-β1 specific antibodies and methods and uses thereof
LUDWIG INST FOR CANCER RES LTD2 citations72
US10947303B2Mar 16, 2021
TGF-ß1 specific antibodies and methods and uses thereof
LUDWIG INST FOR CANCER RES LTD4 citations72